Amaero (3DA) Registration filing summary

Company overview and business model

• U.S.-based producer of high-purity spherical refractory and titanium alloy powders for additive manufacturing, plus large near-net-shape powder metallurgy hot isostatic pressing (PM-HIP) components for defense, aerospace, space, medical, energy and industrial markets.

• EIGA Premium crucible-free atomizers are designed to minimize contamination; the powder portfolio includes niobium, tungsten, tantalum, molybdenum, rhenium, zirconium and titanium alloys.

• PM-HIP consolidates metal powder under heat and isostatic pressure to make dense, complex parts with forged-equivalent properties; positioned as an alternative to capacity-constrained domestic castings and forgings.

• Three atomizers are commissioned; current annual production capacity is 680 metric tons, with a fourth expected in June 2027 to lift planned capacity to 920 metric tons. A 100,000-square-foot Tennessee facility has room for expansion.

• Commercial relationships include five-year or multi-year supply arrangements with ADDMAN Group, Velo3D, Titomic, Knust-Godwin and United Performance Metals; backlog reached $13.4 million across 18 customers at September 30, 2026.

Financial performance and metrics

• FY2025 revenue was $6.305 million versus $1.317 million in FY2024; gross loss was $5.163 million versus $2.843 million, and net loss attributable to stockholders was $18.378 million versus $12.725 million.

• H1 2026 revenue was $7.397 million versus $1.219 million in H1 2025; gross loss was $3.077 million versus $3.277 million, and net loss attributable to stockholders was $13.433 million versus $8.731 million.

• Adjusted EBITDA, a non-GAAP measure, was a loss of $8.512 million in H1 2026 versus a loss of $7.650 million in H1 2025; net cash used in operating activities was $12.903 million versus $6.985 million.

• Cash and cash equivalents were $13.589 million at June 30, 2026; total debt, net, was $19.573 million. The EXIM Bank facility was fully drawn in July 2026.

• Backlog increased from $0.4 million at December 31, 2024 to $6.9 million at December 31, 2025, $10.0 million at June 30, 2026 and $13.4 million at September 30, 2026.

Use of proceeds and capital allocation

• Estimated net proceeds are $15.7 million at the assumed $5.15 per-share IPO price, or $18.5 million if the underwriters exercise their option in full, after estimated discounts, commissions and expenses.

• Up to approximately $10.0 million is planned for capital equipment over the next 12 months; remaining proceeds are for general corporate purposes, including working capital, operating expenses and R&D.

• Potential acquisitions or investments may be considered, but there are no material acquisition or investment commitments; remaining proceeds are intended for capital-preservation investments.

• Proceeds plus existing cash are expected to fund operating expenses and capital expenditures into Q2 2027; additional funding is expected to be needed to continue operations through the next year.